On this page
Permethrin
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Permethrin | 50 mg/100g | 106387 | — |
| Permethrin | 50 mg/g | 106387 | — |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Pyrethrins [CS] | CS | 1 member — no class page |
| Pyrethroid [EPC] | EPC | 1 member — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 211303-001 | PERMETHRIN | CREAM | PERMETHRIN | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | April 3, 2019 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260813). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Permethrin Cream 5% w/w is indicated for the treatment of infestation with Sarcoptesscabiei (scabies).
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Adults and children - Thoroughly massage Permethrin Cream 5% w/w into the skin from the head to the soles of the feet. Scabies rarely infests the scalp of adults, although the hairline, neck, temple, and forehead may be infested in infants and geriatric patients. Usually 30 grams is sufficient for an average adult. The cream should be removed by washing (shower or bath) after 8 to 14 hours. Infants should be treated on the scalp, temple, and forehead. ONE APPLICATION IS GENERALLY CURATIVE . Patients may experience persistent pruritus after treatment. This is rarely a sign of treatment failure and is not an indication for retreatment. Demonstrable living mites after 14 days indicate that retreatment is necessary.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Permethrin Cream 5% w/w is contraindicated in patients with known hypersensitivity to any of its components, to any synthetic pyrethroid or pyrethrin.
Warnings
openFDA Drug LabelingWARNINGS If hypersensitivity to Permethrin Cream 5% w/w occurs, discontinue use.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In clinical trials, generally mild and transient burning and stinging followed application with permethrin cream 5% in 10% of patients and was associated with the severity of infestation. Pruritus was reported in 7% of patients at various times post-application. Erythema, numbness, tingling, and rash were reported in 1 to 2% or less of patients (see PRECAUTIONS-General ). Other adverse events reported since marketing permethrin cream 5% include: headache, fever, dizziness, abdominal pain, diarrhea and nausea and/or vomiting. Although extremely uncommon and not expected when used as directed (see DOSAGE AND ADMINISTRATION ), rare occurrences of seizure have been reported. None have been medically confirmed as associated with permethrin cream 5% treatment. To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION: Permethrin Cream, 5% is a topical scabicidal agent for the treatment of infestation with Sarcoptes scabiei (scabies). It is available in an off-white, greaseless, uniform mass. Permethrin Cream, 5% is for topical use only. Chemical Name - The permethrin used is an approximate 1:3 mixture of the cis and trans isomers of the pyrethroid 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid, (3-phenoxyphenyl) methyl ester. Permethrin has a molecular formula of C 21 H 20 CI 2 O 3 and a molecular weight of 391.29. It is a colorless or slightly brownish viscous liquid, semi-solid or crystalline solid. Active Ingredient - Each gram contains permethrin 50 mg (5%). Inactive Ingredients - Butylated hydroxytoluene, carbomer homopolymer type B, ceteth-2, ceteth-20, glycerin, isopropyl myristate, lanolin alcohols, medium chain triglycerides, mineral oil, mono and di-glycerides, purified water, and sodium hydroxide. Formaldehyde 1 mg (0.1%) is added as a preservative. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE No instance of accidental ingestion of Permethrin Cream 5% w/w has been reported. If ingested, gastric lavage and general supportive measures should be employed. Excessive topical use (see DOSAGE AND ADMINISTRATION ) may result in increased irritation and erythema.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Permethrin Cream 5% w/w is available as follows: 60 g tube 68788-8439-6 STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa – 403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713 USA Rev 04 May 2025 Relabeled By: Preferred Pharmaceuticals Inc.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: PERMETHRIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-5888-0 | 50090-5888 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-5888-0) / 60 g in 1 TUBE | December 30, 2021 |
| 84386-073-60 | 84386-073 | Aurobindo Pharma Limited | 1 TUBE in 1 CARTON (84386-073-60) / 60 g in 1 TUBE | January 22, 2024 |
| 71335-2899-1 | 71335-2899 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2899-1) / 60 g in 1 TUBE | October 24, 2025 |
| 72162-2171-6 | 72162-2171 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2171-6) / 60 g in 1 TUBE | December 7, 2023 |
| 43598-481-60 | 43598-481 | Dr. Reddy's Laboratories, Inc. | 1 TUBE in 1 CARTON (43598-481-60) / 60 g in 1 TUBE | August 26, 2026 |
| 21922-021-07 | 21922-021 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-021-07) / 60 g in 1 TUBE | April 8, 2019 |
| 16714-897-01 | 16714-897 | Northstar Rx LLC | 1 TUBE in 1 CONTAINER (16714-897-01) / 60 g in 1 TUBE | April 8, 2019 |
| 45802-269-37 | 45802-269 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-269-37) / 60 g in 1 TUBE | August 11, 2006 |
| 68788-8439-6 | 68788-8439 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8439-6) / 60 g in 1 TUBE | June 5, 2023 |
| 70518-2945-0 | 70518-2945 | REMEDYREPACK INC. | 1 TUBE in 1 CARTON (70518-2945-0) / 60 g in 1 TUBE | April 8, 2019 |
| 50090-5888 | 50090-5888 | A-S Medication Solutions | — | April 8, 2019 |
| 84386-073 | 84386-073 | Aurobindo Pharma Limited | — | January 22, 2024 |
| 71335-2899 | 71335-2899 | Bryant Ranch Prepack | — | August 11, 2006 |
| 72162-2171 | 72162-2171 | Bryant Ranch Prepack | — | August 11, 2006 |
| 43598-481 | 43598-481 | Dr. Reddy's Laboratories, Inc. | — | August 26, 2026 |
| 21922-021 | 21922-021 | Encube Ethicals, Inc. | — | April 8, 2019 |
| 16714-897 | 16714-897 | Northstar Rx LLC | — | April 8, 2019 |
| 45802-269 | 45802-269 | Padagis Israel Pharmaceuticals Ltd | — | August 11, 2006 |
| 68788-8439 | 68788-8439 | Preferred Pharmaceuticals Inc. | — | June 5, 2023 |
| 70518-2945 | 70518-2945 | REMEDYREPACK INC. | — | April 8, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.